Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. (Q36929947)
Jump to navigation
Jump to search
scientific article published on 30 April 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. |
scientific article published on 30 April 2013 |
Statements
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus (English)
Elizabeth K Hussey
Anita Kapur
Robin O'Connor-Semmes
Wenli Tao
Bryan Rafferty
Charles D James
Robert L Dobbins
30 April 2013
1 reference
1 reference
1 reference